Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02453334 · ClinicalTrials.gov registry record · Phase 3
Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 244
- Enrollment target
NCT02453334 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 244 participants.
The verdict
NCT02453334, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 244 participants
- Enrollment target
Study Summary
Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study.
Interventions
- OTHER Normal Saline
- DRUG Injectafer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2015-05-23 |
| Est. Completion | 2018-01-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02453334
The ClinicalTrials.gov registry entry for NCT02453334 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT02453334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02453334 about?
NCT02453334 is a clinical study titled "Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®". Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study.
What is the current status of trial NCT02453334?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 244 participants. The study started on 2015-05-23. Estimated completion is 2018-01-04.
What interventions are being tested in trial NCT02453334?
The interventions under investigation include: Normal Saline (OTHER), Injectafer (DRUG).
Who is sponsoring clinical trial NCT02453334?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.